Pfizer and BMS present new apixaban data
3 September 2008 00:00 in Pharmaceutical Company Product News
Pfizer and Bristol-Myers Squibb have announced the publication of new data on investigational anticoagulant apixaban in patients with acute coronary syndrome.
The companies presented the results of the phase II Appraise-1 dose-ranging study of the drug in patients taking commonly-used anti-platelet therapies, comparing the current standard of care including aspirin and clopidogrel with apixaban together with this standard.
Pfizer said the six-month study was not powered to show significance on the composite endpoint of non-haemorrhagic stroke, severe recurrent ischemia, non-fatal heart attack and cardiovascular death, though a non-significant relative risk reduction was observed compared to placebo.
The results were presented at a late-breaking session of the annual meeting of the European Society of Cardiology in Munich, Germany.
John H Alexander, of the Duke Clinical Research Institute and Duke Heart Centre in Durham, North Carolina, said: "The Appraise-1 study provided encouraging trends suggesting that anticoagulation with apixaban on top of current standards of care and continued beyond the initial hospitalisation period may reduce the risk of a second heart attack, stroke or death."
He added there was a trade-off with some increase in bleeding observed, as there are with all effective anticoagulants, while the company is looking forward to further studies of the compound.
Pfizer and BMS signed their global partnership agreement for the development and commercialisation of apixaban as a treatment for arterial and venous thrombotic conditions in April 2007.
Other news stories from 03/09/2008
Read more in the Zenopa News Archive
How this news is generated
Story collated for Zenopa by the Adfero News Agency